| Literature DB >> 31142876 |
S B Shah1, U Hariharan2, R Chawla1.
Abstract
Integrating perioperative medicine with anaesthesia is the need of the hour. Evolution of a new superspeciality called perioperative anaesthesia can improve surgical outcomes by quality perioperative care and guarantee imminent escalation of influence and power for anaesthesiologists. All original peer-reviewed manuscripts pertaining to surgery-specific perioperative surgical home models involving preoperative, intraoperative and postoperative initiatives spanning the past 5 years have been reviewed using PubMed and Google Scholar. Whether the perioperative surgical home model is feasible or still a distant dream in the Indian perspective has been analysed.Entities:
Keywords: Enhanced recovery after surgery; perioperative medicine; surgical home
Year: 2019 PMID: 31142876 PMCID: PMC6530285 DOI: 10.4103/0019-5049.258058
Source DB: PubMed Journal: Indian J Anaesth ISSN: 0019-5049
Figure 1(Original): Organisation of enhanced perioperative care model with the anaesthetist at the hub centre
Review of randomised controlled trials spanning past 5 years pertaining to ERAS and PSH models
| Surgery original study/year | Participants ( | Outcome |
|---|---|---|
| ERAS (oesophageal cancer) | ||
| Ford | 75 (ERAS) | ↓Mortality (0 ERAS; 3 control) |
| Pan | 40 (ERAS) | ↓LOS (from 12 to 8 d) |
| Al-Herz | 30 (ERAS) | ↓LOS (from 15 to 13 d) |
| Shewale | 386 (ERAS) | ↓LOS (12 to 8d); ↓Pul. complications (76 ERAS; 88 Control) ↓ leak anastomotic (45 ERAS; 49 control) ↓Mortality (9 ERAS; 11 control) |
| Wang | 90 (ERAS) | ↓LOS (from 11.7 to 9 d) |
| Findlay | 55 (ERAS) | ↓Mortality (1 in ERAS; 3 control) |
| ERAS (pancreatic surgery) | ||
| Braga | 115 (ERAS) | ↓LOS: 14.6 d ERAS, 16.1 d control; ↓delayed gastric emptying: 11 ERAS, 17 control; morbidity: 69 ERAS, 76 control; mortality: 4 ERAS, 4 control; readmission rate: 14 ERAS; 12 control; reoperation rate: 14 ERAS; 12 control |
| Pillai | 20 (ERAS) | ↓LOS :15.75 d ERAS; 22 d control; delayed gastric emptying: 7 ERAS; 15 control; morbidity: 9 ERAS; 5 controlMortality: 2 ERAS; 1 control; readmission rate: 0 ERAS; 0 control; reoperation rate: 3 ERAS; 1 control |
| Coolsen | 86 (ERAS) | ↓LOS: 13 d ERAS; 20 d control; gastric emptying time: 11 ERAS; 7 control; morbidity: 46 ERAS; 48 controlMortality: 4 ERAS; 6 control; readmission rate: 11 ERAS; 14 control; reoperation rate: 7 ERAS; 13 control |
| Nussbaum | 100 (ERAS) | ↓LOS :11 d ERAS; 13 d control; delayed gastric emptying: 17 ERAS; 23 control; mortality: 1 ERAS; 4 control; readmission: 31 ERAS; 36 control; reoperation: 10 ERAS; 18 control |
| Sutcliffe | 44 (ERAS) | ↓LOS: 7 d ERAS; 9 d control; delayed gastric emptying: 2 ERAS; 3 control; morbidity: 15 ERAS; 15 control; mortality: 2 ERAS; 0 control; readmission rate: 1 ERAS; 6 control |
| Morales Soriano | 50 (ERAS) | ↓LOS (postop) :14.2 d ERAS; 18.7 d control; delayed gastric emptying: 1 ERAS; 3 control; morbidity: 12 ERAS; 24 control; mortality: 0 ERAS; 2 control; readmission rate: 4 ERAS; 4 control; reoperation rate: 5 ERAS; 5 control |
| Williamsson | 41 (ERAS) | ↓LOS (postop) :10 d ERAS; 14 d control; delayed gastric emptying: 13 ERAS; 24 control; morbidity: 32 ERAS; 34 control; no mortality (both); readmission: 3 ERAS; 3 control |
| ERAS (pancreaticodudenectomy) | ||
| Shao | 325 (ERAS) | ↓LOS (postop): 13.9 d ERAS; 17.6 d control; delayed gastric emptying: 29 ERAS; 52 control; overall complications: 127 ERAS; 173 control; readmission rate: 43 ERAS; 44 control |
| Zouros | 75 (ERAS) | Delayed gastric emptying: 9 ERAS; 15 control; complications: 27 ERAS; 25 control; mortality: 3 ERAS; 2 control; readmission rate: 5 ERAS; 3 control; reoperation rate: 4 ERAS; 2 control |
| Bai | 124 (ERAS) | Delayed gastric emptying: 11 ERAS; 10 control; complications: 84 ERAS; 46 control; mortality: 1 ERAS; 1 control; readmission rate: 11 ERAS; 2 control; reoperation rate: 4 ERAS; 1 control |
| Dai | 68 (ERAS) | ↓LOS (postop): 7.5 d ERAS; 12 d control; delayed gastric emptying: 0 ERAS; 11 control; ↓complications: 34 ERAS; 89 control; mortality: 0 ERAS; 0 control; readmission: 0 ERAS; 6 control; reoperation: 2 ERAS; 5 control |
| ERAS (Laparoscopic total/radical gastrectomy) | ||
| Gowda | 22 (ERAS) | ↓LOS: 78 h ERAS, 140 h control; early passage of flatus (37 vs. 74 h); no significant difference in complications; ↓serum CRP in ERAS [d 1: (52.4 vs 73.0 g/L; d 3: (126.1 vs 160.7g/L)] |
| Fujikini | 40 (ERAS) | HOMA-R index score >2.5 means insulin resistance; ↓HOMA-R score on 1st postop day (15 ERAS; 6.6 control) |
| Abdikarim | 30 (ERAS) | ↓LOS (postop) 6.8 d ERAS; 7.7 d control↓Hospital charge; ↓complications 1 ERAS; 2 control |
| Liu | 21 (ERAS) | ↓LOS (postop) 6.3 d ERAS; 7.8 d control; ↓time to first flatus 48 h ERAS; 60 h control; ↓hospital charge $4884 ERAS; $5626 control; ↓complications 11 ERAS; 6 control |
| Fang | 33 (ERAS) | ↓LOS (postop) 11 d ERAS; 18.5 d control; ↓time to first flatus 60 h ERAS; 96 h control; ↓complications 2 ERAS; 2 control |
| Mingjie | 73 (ERAS) | ↓LOS (postop) 6.38 d ERAS; 8.62 d control ↓Complications 2 ERAS; 2 control |
| Tanaka | 73 (ERAS) | ↓LOS 9 d ERAS, 10 d control; ↓major postop complications (4.1% ERAS; 15.4% control); ↓costs of hospitalisation (JPY 1,462,766 vs JPY 1,493,930); ↑ physical activity 1st week post-surgery |
| ERAS (lung cancer surgery) | ||
| Lai | 24 (ERAS) | ↓LOS (hospital): 14 d (ERAS), 15.8 d (control); ↓total cost: 46.5 (ERAS), 45.5 (control); no in-hospital mortality in both groupsOverall morbidity: 2 (ERAS) 5 (control) |
| Dong | 17 (ERAS) | ↓LOS (hospital):18.1 d (ERAS), 27.4 d (control); ↓total cost: 29.9 (ERAS), 37.2 (control); no in-hospital mortality in both groups; overall morbidity: 4 (ERAS), 6 (control) |
| Huang | 30 (ERAS) | ↓LOS (hospital): 14.1 d (ERAS), 17.3 d (control); ↓in-hospital mortality; ↓overall morbidity: 5 (ERAS), 12 (control) |
| Licker | 74 (ERAS) | ↓LOS (hospital):10 d (ERAS), 9 d (control); ↓LOS (ICU): 0.7 d (ERAS), 1 d (control); overall morbidity: 27 (ERAS), 39 (control) |
| ERAS (open radical cystectomy) | ||
| Persson | 31 (ERAS) | ↓Time to first passage of stool ↓30-d readmission frequency |
| Collins | 135 (ERAS) | ↓LOS (postop) 8 d ERAS; 9 d control; change in demographics with↓median age from 66 (control) to 70 years (ERAS) |
| Lin | 124 (ERAS) | ↓ LOS (9.2 to 3.8 d), ↓hospitalisation costs from USD 7200 to USD 6100; ↓time to first water intake (2.5 h ERAS; 30.1 h control); first ambulation (8.7 h ERAS; 73 h control), first defecation (17 h ERAS; 81 h control) |
| ERAS (gynaecological) surgeries | ||
| Modesitt | 136 (ERAS) | ↓LOS (postop): 2 d ERAS; 3 d control; ↓ median intraop morphine equivalents (0.3 ERAS; 12.7 mg control) |
| PSH (Lean Six Sigma; posterior spinal fusion scoliosis surgery) | ||
| Thomson | 27 (PSH) | ↓LOS (5.2 vs 3.4 d); no difference in 30-d readmission rate; no mortality in either group↓Perioperative blood transfusion (35% vs 11%, OR=0.21) |
| PSH (total knee arthroplasty/total hip arthroplasty) | ||
| Qiu | 546 (Reference) | ↓LOS (2.4 vs 3.4 d); ↑SNF bypass rate in PSH group (94% vs 80%); no difference in 30 readmission (1.2% vs 0.98%) |
| Vetter | 1225 (Pre-PSH) | $432 and $601 decrease in direct nonsurgical costs for post PSH patients; ↑on-time surgery starts;↓anaesthesia related delays; ↓ day-of-surgery case cancellations |
ERAS–Enhanced recovery after surgery; PSH–Perioperative surgical home; CRP–C-reactive protein; HOMA-R–Homeostasis model assessment-insulin resistance; ICU–Intensive care unit; LOS–Length of stay; OR–Odds ratio; Pul–Pulmonary; h–Hours; d–Days; THA–Total hip replacement; TKA–Total knee replacement
Perioperative Surgical Home model for robotic radical hysterectomy and robot-assisted radical prostatectomy
| Timing | Technique | Technique | Technique | Technique |
|---|---|---|---|---|
| Before Sx | Standardise duration of Sx to 2 h | Two robotic OTs assigned for RH cases taken up in batches of 2-3 per OT | Real-time feedback on cancelled/added/rescheduled cases | Patient shifted to OT with minimal waiting period for the patient and without wastage of OT time |
| Presurgical care | Patient education on available alternative Sx | Informed consent after disclosing complications including conversion to open Sx | Infection prevention strategies discussed with patient | Surgeon enters admission orders by 5 PM a day prior to Sx |
| preanaesthetic care | Triage system to identify patients requiring prehabilitation in preadmission clinics; CPET | PAC checkup 1-7 d before SxDiscontinue anticoagulants as per guidelines | Optimisation of medication (HTN, DM, hypothyroid, OSA) and screening for glaucoma and raised ICP | Clear Malto dextrin drink (Ensure/Gatorade) 400 mL or 50 g; 2 h before Sx |
| Communication | Centralised electronic system with access to patient information for all stakeholders | Team member and team leader identification | Anaesthesia technician assigned for the case | Cleaning staff, OT technician and nurse to start cleaning and set up OT as soon as incision is closed |
| Robot and instruments on day of Sx | Standardisation of equipment and instruments across surgeons | Availability of minimum number of instrument trays/sets required to avoid the need for processing/sterilisation between cases | All trays complete and in working order | Tray available for conversion to open Sx |
| Preop | Activation of multimodal pain and PONV prevention protocol; iv PCM 1 g before docking | Combination approach for positioning patient in ST position: placement of a horizontal sheet in the anatomical concavity of the back; patient’s torso and hips on a hypoallergenic warming gel pad with a high coefficient of friction; sandwiching gel pads between the shoulder and brace; placing shoulder braces more medially (flush with the head) VTE prophylaxisAntibiotic 1 h before Sx | Padding of pressure points | |
| Intraop | Intraop timeoutSafety checklist signed by surgeon and anaesthetist in CPRS (electronic records) | VCV keeping peak airway pressure <30 mmHgSwitch over to PCV to avoid barotrauma in head low position | Remember to reduce set control pressure/switch over to VCV once patient is supine again | Glitch book used if problems with docking of robot |
| Fluid restriction, 8 mg dexamethasone, 10-20 mg furosemide and/or mannitol to prevent POCD | Maintaining depth of anaesthesia with BIS; keeping <10 PTCs with PNS to avoid patient movement with robot docked | Fluid chasing and slight head up position after dedocking and supination | Sign out after final instrument and swab count coincides with initial count | |
| Postop | Quick dressing and handover to OT anaesthesiologist for reversal and handover to SICU anaesthetist | SICU complications attended to timely by anaesthetist; Aldrete discharge criteria met for discharge to ward; PASS score >13 for discharge homePrescription analgesic in discharge order | VAS 1-3: diclofenac 50 mg 8 hourlyVAS 4-6: tramadol 50 mg SOS and 6 hourlyVAS 7-10: fentany l 50 µg SOS | For PONVIV ondensetron 4-8 mg and/or IV dexamethasone 4-8 mgAvoid morphineRemoval of nasogastric tube early enteral feed |
| Preparedness for next case | One member of OT cleaning staff immediately available on incision closure | Next patient trolley immediately wheeled into the OT by OT technician the moment the cleaning staff exits | Preoperative checklist completed timely by surgeon and anaesthetist | Real-time next-patient status update with information on potential delays |
| Post discharge care | Follow-up with phone calls (d 3 and d 5); clinical visits | Tracking of emergency care returns and noting the causes | Any requirement for readmission | Monthly reviews by robotic committee |
CPET–Cardiopulmonary exercise testing; DM–Diabetes mellitus; HTN–Hypertension; Intraop–Intraoperative; OSA–Obstructive sleep apnoea; OT–Operation theatre; PONV–Postoperative nausea and vomiting; Postop–Postoperative; SICU–Surgical intensive care unit; Sx–Surgery; VAS–Visual analog score; VTE–Venous thromboembolism
PSH model for major head and neck Sx requiring free-flap reconstruction
| Timing | Technique | Technique | Technique |
|---|---|---|---|
| Before Sx | Case to be started as the first case to allow adequate time for assessing free-flap perfusion | Real-time feedback on cancelled/added/rescheduled cases | Patient shifted to OT with minimal waiting period for the patient and without wastage of OT time |
| Presurgical care | Informed consent after disclosing complications including flap necrosis, need for tracheostomy and cosmetic disfigurement | Infection prevention strategies discussed with patient | Surgeon enters admission order by 5 PM the day prior to Sx |
| Preanaesthetic care | PAC checkup 1-7 d before SxDiscontinue anticoagulants as per guidelines | Patient counselled about postoperative retention of ETT and inability to speak with ETT | Patient counselled about awake fibreoptic intubation under local anaesthetic nerve blocks where required |
| Lab investigationsCBC, KFT incl S. electrolytesLFT incl. S. proteinsCoagulation profileRBS, TSH, CXR, ECG (echo if post CT; stress test for CAD)Viral markers | Difficult airway assessment and management plan especially for SMF patients with restricted mouth opening and redo cases (C Mac Dblade; FOB) | PONV preventionActivate multimodal analgesia (including preemptive analgesia) on arrival | |
| Communication | Avoid taking IV access, CVP or arterial line from the limb from which free flap is to be harvested | Anaesthesia technician assigned for the case | Site and side of Sx marked |
| Instruments on day of Sx | Availability of venous couplers for anastomosis, angle plates/implants | Instruments tray verified to be complete and in working order for the day | Difficult airway cartC Mac D blade videolaryngoscopeFOB; bougie |
| Preop | Medication optimisation (HTN, DM, hypothyroid, OSA) | Nostril selection (digital method; MRI imaging on display; POC USG) | Activate multimodal analgesia (including preemptive analgesia) on arrival (1 g PCM iv) |
| Intraop | Nostril preparation with oxymetazoline drops | Flexometallic tube | |
| Heparin 2500 IU after harvesting but before free-flap insertion | Hypothermia prevention (warming blanket, fluid warmer) to improve rheology | Point-of-care blood sugar and free-flap sugar to be estimated and a difference of <10 mg% to be maintained | |
| Postop | Noting time of extubation over bougie following morning | Early ambulation | No routine lab investigations (need based on consensus) |
| Early removal of urinary catheter | |||
| Quality improvement post discharge | Tracking of emergency care returns and noting the causes | Noting incidence of reexploration/flap revision/reanastomosis for flap necrosis or any bleeders causing haemodynamic compromise | Monthly review by head and neck Sx review committee and feedback to stakeholders: oncosurgeon, plastic surgeon anaesthetist, nurse |
PSH–Perioperative Surgical Home; CAD–Coronary artery disease; CT–Chemotherapy; DM–Diabetes mellitus; FOB–Fiberoptic bronchoscope; HTN–Hypertension; OSA–Obstructive sleep apnoea; OT–Operation theatre; PCM–Paracetamol; POC–Point of care; PVI–Pleth variability index; RT–Radiotherapy; RIOT–Return to intended oncotherapy; SVV–Stroke volume variation; USG–Ultrasound